Recent Updates
Recently added Catalysts

intra- ketorolac

Phase 2

Post Operative Pain | Small molecule | Pain |Assertio Holdings, Inc.|Last Updated: Apr 18, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLED
Total Trials1
Total Enrollment80
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06158620Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone DiseasePHASE2 RECRUITING 80Mar 1, 2025Dec 1, 2026Apr 18, 20251 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
intra-nasal ketorolacDRUGExperimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
oral diclofenacDRUGControl group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06158620studyFirstPostDate: changed